{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:42:13Z","timestamp":1788176533958,"version":"build-2803163510"},"reference-count":21,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"name":"National Center for Tumor Diseases (NCT) Heidelberg","award":["Heidelberg School of Oncology (HSO2)"],"award-info":[{"award-number":["Heidelberg School of Oncology (HSO2)"]}]},{"DOI":"10.13039\/100009162","name":"Hairy Cell Leukemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009162","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Else Kroener Fresenius Foundation"},{"name":"Heidelberg Research Centre for Molecular Medicine"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["e:med junior grant"],"award-info":[{"award-number":["e:med junior grant"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB873"],"award-info":[{"award-number":["SFB873"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed and refractory mantle cell lymphoma (r\/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 patients aged \u226550 years with r\/r MCL treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (of 272) patients with r\/r MCL who underwent alloHCT using data from the European Society for Blood and Marrow Transplantation registry. The median follow-up time was 36.5 months for the brexu-cel cohort and 34.1 months for the matched alloHCT cohort. Patients who received brexu-cel had a significantly higher overall survival [(OS) 81.3% vs. 59.2%; HR, 0.39; P = 0.004] and lower nonrelapse mortality (3.6% vs. 21.2%; P = 0.015) 1 year after treatment. Chronic GVHD occurred within the first year in 26.9% of patients who underwent alloHCT. However, long-term progression-free survival (PFS) and OS remain comparable. Despite the limitations of this nonrandomized study, the findings indicate a superior safety profile for brexu-cel in r\/r MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Patients aged \u226550 years with r\/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk\u2013benefit evaluation is essential to guide optimal treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0178","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:33:46Z","timestamp":1738845226000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3887-9416","authenticated-orcid":false,"given":"Nora","family":"Liebers","sequence":"first","affiliation":[{"name":"1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany."},{"name":"2Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany."},{"name":"3Center for Integrated Oncology Aachen-Bonn-Cologne-D\u00fcsseldorf (CIO ABCD), Aachen Bonn Cologne D\u00fcsseldorf, Cologne, Germany."},{"name":"4Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2552-0542","authenticated-orcid":false,"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Finel","sequence":"additional","affiliation":[{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7467-6343","authenticated-orcid":false,"given":"Dominic","family":"Edelmann","sequence":"additional","affiliation":[{"name":"6Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9745-8813","authenticated-orcid":false,"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany."},{"name":"3Center for Integrated Oncology Aachen-Bonn-Cologne-D\u00fcsseldorf (CIO ABCD), Aachen Bonn Cologne D\u00fcsseldorf, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1699-9478","authenticated-orcid":false,"given":"Ben-Niklas","family":"Baermann","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany."},{"name":"3Center for Integrated Oncology Aachen-Bonn-Cologne-D\u00fcsseldorf (CIO ABCD), Aachen Bonn Cologne D\u00fcsseldorf, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-5725","authenticated-orcid":false,"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[{"name":"8Institut Paoli Calmettes, Marseille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-220X","authenticated-orcid":false,"given":"Dietrich Wilhelm","family":"Beelen","sequence":"additional","affiliation":[{"name":"9University Hospital Essen, Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"10Hospital Clinico Universitario-INCLIVA, University of Valencia, Valencia, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-1632","authenticated-orcid":false,"given":"Maija","family":"It\u00e4l\u00e4-Remes","sequence":"additional","affiliation":[{"name":"11University Hospital Turku, Turku, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-6950","authenticated-orcid":false,"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[{"name":"12University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2067-9750","authenticated-orcid":false,"given":"Goda","family":"Choi","sequence":"additional","affiliation":[{"name":"12University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5941-3673","authenticated-orcid":false,"given":"Susanne Anna Christine","family":"Schmidt","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany."},{"name":"3Center for Integrated Oncology Aachen-Bonn-Cologne-D\u00fcsseldorf (CIO ABCD), Aachen Bonn Cologne D\u00fcsseldorf, Cologne, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"13University Medical Center Hamburg, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7576-2787","authenticated-orcid":false,"given":"Jenny","family":"Byrne","sequence":"additional","affiliation":[{"name":"14Nottingham University, Nottingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-8106","authenticated-orcid":false,"given":"Jean-Jacques","family":"Tudesq","sequence":"additional","affiliation":[{"name":"15CHU Lapeyronie, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-0065","authenticated-orcid":false,"given":"Anna","family":"Ossami Saidy","sequence":"additional","affiliation":[{"name":"16Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7481-9550","authenticated-orcid":false,"given":"Ana","family":"Nunes","sequence":"additional","affiliation":[{"name":"17Kite, a Gilead Company, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0244-1531","authenticated-orcid":false,"given":"Rubina","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"17Kite, a Gilead Company, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8566-6828","authenticated-orcid":false,"given":"Elande","family":"Baro","sequence":"additional","affiliation":[{"name":"17Kite, a Gilead Company, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6516-1723","authenticated-orcid":false,"given":"Dan","family":"Zheng","sequence":"additional","affiliation":[{"name":"17Kite, a Gilead Company, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3243-8450","authenticated-orcid":false,"given":"Ioana","family":"Kloos","sequence":"additional","affiliation":[{"name":"17Kite, a Gilead Company, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany."},{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."},{"name":"18Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-L\u2019Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0816-688X","authenticated-orcid":false,"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."},{"name":"16Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-1832","authenticated-orcid":false,"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Duesseldorf, Germany."},{"name":"3Center for Integrated Oncology Aachen-Bonn-Cologne-D\u00fcsseldorf (CIO ABCD), Aachen Bonn Cologne D\u00fcsseldorf, Cologne, Germany."},{"name":"4Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany."},{"name":"5Lymphoma Working Party, European Society for Blood and Marrow Transplantation, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2026041309325983100_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2026041309325983100_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"2026041309325983100_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2026041309325983100_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041309325983100_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2026041309325983100_bib6","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/cancers14112673","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma; insights into its potential role in the era of new immunotherapeutic and targeted therapies: the GETH\/GELTAMO experience","volume":"14","author":"Gutierrez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026041309325983100_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2018.1468894","article-title":"Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study","volume":"60","author":"Sandoval-Sus","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026041309325983100_bib8","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"2026041309325983100_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041309325983100_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041309325983100_bib11","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1016\/S2352-3026(23)00335-6","article-title":"CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma","volume":"10","author":"Iacoboni","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026041309325983100_bib12","first-page":"720","article-title":"American society of transplantation and cellular therapy, center of international blood and marrow transplant research, and European society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma","volume":"27","author":"Munshi","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2026041309325983100_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41409-020-0976-4","article-title":"The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis","volume":"56","author":"Selberg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026041309325983100_bib14","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041309325983100_bib15","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041309325983100_bib16","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"2026041309325983100_bib17","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"key":"2026041309325983100_bib18","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"2026041309325983100_bib19","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041309325983100_bib20","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041309325983100_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0178\/3540020\/bcd-24-0178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0178\/3562373\/bcd-24-0178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/182\/3601206\/bcd-24-0178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/182\/3601206\/bcd-24-0178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:33:12Z","timestamp":1776087192000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/182\/762113\/Brexucabtagene-Autoleucel-versus-Allogeneic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0178","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7801750","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.28929652","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929673","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929661","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929682","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929670","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929649","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929658","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929667","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929655","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929676","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929664","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}